Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kezar Life Sciences Inc
(NQ:
KZR
)
0.6652
-0.0148 (-2.18%)
Streaming Delayed Price
Updated: 11:15 AM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kezar Life Sciences Inc
< Previous
1
2
3
4
5
6
Next >
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 13, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 07, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Wells Fargo Beefs Up Kezar Life Price Target - Read Why
June 28, 2022
Via
Benzinga
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
November 14, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
November 11, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
November 09, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
November 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting
October 14, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 06, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Why Kezar Life Sciences Shares Are Volatile After Hours
October 03, 2022
Kezar Life Sciences Inc (NASDAQ: KZR) shares are trading higher in Monday's after-hours session after the company announced that it has received clearance of its Investigational New Drug (IND)...
Via
Benzinga
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis
October 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022
September 29, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 02, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
September 01, 2022
From
Kezar Life Science
Via
Business Wire
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 03, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
July 11, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating
July 08, 2022
The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81.
Via
Investor's Business Daily
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
July 07, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 06, 2022
From
Kezar Life Sciences, Inc.
Via
Business Wire
The Week In Charts: How To Make Money While Waiting For Core Trend Trades
July 02, 2022
The real money is in the longer-term core trend trades. However, sometimes those opportunities can be few and far between. This is especially true in a bear market.
Via
Talk Markets
Biotech ETF Tops in June: 5 Stocks That Outperform
June 30, 2022
Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%.
Via
Talk Markets
Short Volatility Alert: Kezar Life Sciences, Inc.
June 29, 2022
On Tuesday, shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) experienced volatile short activity. After the activity, the stock price went up +43.43% to $8.29. The overall sentiment for KZR has been...
Via
Benzinga
InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday
June 29, 2022
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.
Via
Benzinga
Dow Dips Over 400 Points; Crude Oil Rises 2%
June 28, 2022
U.S. stocks turned sharply lower toward the end of trading, with the Dow Jones dropping more than 400 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
June 28, 2022
Gainers
Via
Benzinga
Nasdaq Turns Lower; Kezar Life Sciences Shares Jump
June 28, 2022
U.S. stocks pared gains midway through trading, with the Nasdaq Composite and S&P 500 turning lower on Tuesday.
Via
Benzinga
Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session
June 28, 2022
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.